Skip to main content
SpringerLink
Log in

Prostate cancer

Clinical implications of therapeutic sequence in mCRPC

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

In the field of advanced prostate cancer, a number of therapeutic agents are now available. The sequence of administration of medications with distinct mechanisms of action, toxicities and efficacies, will have a critical role in disease outcomes. The identification of biomarkers predicting response will help to determine the appropriate therapeutic sequence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nadal, R. et al. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 74, 1560–1568 (2014).

    Article  CAS  Google Scholar 

  2. Schweizer, M. T. et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur. Urol. 66, 646–652 (2014).

    Article  CAS  Google Scholar 

  3. Azad, A. A. et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 74, 1544–1550 (2014).

    Article  CAS  Google Scholar 

  4. Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial [abstract LBA2]. J. Clin. Oncol. 32 (Suppl.), 5s (2014).

    Google Scholar 

  5. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    CAS  Google Scholar 

  6. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

    Article  Google Scholar 

  7. Ryan, C. et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy [abstract 7530]. Ann. Oncol. 25 (Suppl. 4), iv255–iv279 (2014).

    Article  Google Scholar 

  8. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

    Article  Google Scholar 

  9. Suzman, D. L. & Antonarakis, E. S. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther. Adv. Med. Oncol. 6, 167–179 (2014).

    Article  Google Scholar 

  10. Aparicio, A. M. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19, 3621–3630 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, 4233 HWCRC, Detroit, 48201, MI, USA

    Ulka Vaishampayan

Authors
  1. Ulka Vaishampayan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulka Vaishampayan.

Ethics declarations

Competing interests

U.V. is a speaker for Bayer, Janssen and Astellas/Medivation, a consultant for Astellas/Medivation, and has research support from Astellas/Medivation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vaishampayan, U. Clinical implications of therapeutic sequence in mCRPC. Nat Rev Urol 12, 13–14 (2015). https://doi.org/10.1038/nrurol.2014.308

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.308

  • Springer Nature Limited

Search

Navigation